Effectiveness of ICD therapy in real clinical practice. The Olomouc ICD Registry.
appropriate shock
heart failure
implantable cardioverter-defibrillator
mortality
primary prevention
time to shock
Journal
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
ISSN: 1804-7521
Titre abrégé: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
Pays: Czech Republic
ID NLM: 101140142
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
23
09
2021
accepted:
08
12
2021
medline:
3
11
2023
pubmed:
18
12
2021
entrez:
17
12
2021
Statut:
ppublish
Résumé
Clinical parameters linked to a low benefit of ICD implantation and increased mortality risks are needed for an individualized assessment of potential benefits and risks of ICD implantation. Analysis of a prospective registry of all patients hospitalized from 2009 to 2019 in a single centre for a first implantation of any type of ICD. A total of 2,681 patients were included in the registry. Until the end of follow-up (38.4 ± 29.1 months), 682 (25.4%) patients died. The one-year mortality in all patients, the one-year CV mortality, the three-year mortality in all patients, and the three-year CV mortality were 7.8%, 5.7%, 20.6%, and 14.8%, respectively. There was a statistically significant difference when the subgroups were compared according to the type of cardiomyopathy. No significant difference was found between primary and secondary prevention and between the types of devices. Male gender, age ≥ 75 years, diabetes mellitus, and atrial fibrillation were associated with a significantly increased mortality risk. In an analysis of a long-term follow-up of 2,681 ICD patients, we found no mortality difference between patients with ischemic or non-ischemic cardiomyopathy and in the device type. A higher mortality risk was found in men, patients older than 75 years, diabetics, and those with atrial fibrillation.
Sections du résumé
BACKGROUND
BACKGROUND
Clinical parameters linked to a low benefit of ICD implantation and increased mortality risks are needed for an individualized assessment of potential benefits and risks of ICD implantation.
METHODS
METHODS
Analysis of a prospective registry of all patients hospitalized from 2009 to 2019 in a single centre for a first implantation of any type of ICD.
RESULTS
RESULTS
A total of 2,681 patients were included in the registry. Until the end of follow-up (38.4 ± 29.1 months), 682 (25.4%) patients died. The one-year mortality in all patients, the one-year CV mortality, the three-year mortality in all patients, and the three-year CV mortality were 7.8%, 5.7%, 20.6%, and 14.8%, respectively. There was a statistically significant difference when the subgroups were compared according to the type of cardiomyopathy. No significant difference was found between primary and secondary prevention and between the types of devices. Male gender, age ≥ 75 years, diabetes mellitus, and atrial fibrillation were associated with a significantly increased mortality risk.
CONCLUSION
CONCLUSIONS
In an analysis of a long-term follow-up of 2,681 ICD patients, we found no mortality difference between patients with ischemic or non-ischemic cardiomyopathy and in the device type. A higher mortality risk was found in men, patients older than 75 years, diabetics, and those with atrial fibrillation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
225-235Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346(12):877-83. doi: 10.1056/NEJMoa013474
pubmed: 11907286
doi: 10.1056/NEJMoa013474
Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350(21):2151-8. doi: 10.1056/NEJMoa033088
pubmed: 15152060
doi: 10.1056/NEJMoa033088
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352(3):225-37. doi: 10.1056/NEJMoa043399
pubmed: 15659722
doi: 10.1056/NEJMoa043399
Barra S, Providência R, Narayanan K, Boveda S, Duehmke R, Garcia R, Leyva F, Roger V, Jouven X, Agarwal S, Levy WC, Marijon E. Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. Eur Heart J 2020;41(21):1976-86. doi: 10.1093/eurheartj/ehz773
pubmed: 31750896
doi: 10.1093/eurheartj/ehz773
Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV. Declining Risk of Sudden Death in Heart Failure. N Engl J Med 2017;377(1):41-51. doi: 10.1056/NEJMoa1609758
pubmed: 28679089
doi: 10.1056/NEJMoa1609758
Sabbag A, Suleiman M, Laish-Farkash A, Samania N, Kazatsker M, Goldenberg I, Glikson M, Beinart R; Israeli Working Group of Pacing and Electrophysiology. Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: From the Israeli ICD Registry. Heart Rhythm 2015;12(12):2426-33. doi: 10.1016/j.hrthm.2015.08.020
pubmed: 26277863
doi: 10.1016/j.hrthm.2015.08.020
Narayanan K, Reinier K, Uy-Evanado A, Teodorescu C, Chugh H, Marijon E, Gunson K, Jui J, Chugh SS. Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community. Circulation;128(16):1733-8. doi: 10.1161/CIRCULATIONAHA
doi: 10.1161/CIRCULATIONAHA
Olsen T, Jørgensen OD, Nielsen JC, Thøgersen AM, Philbert BT, Johansen JB. Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982-2018). Eur Heart J 2019;40(23):1862-69. doi: 10.1093/eurheartj/ehz316
pubmed: 31155647
doi: 10.1093/eurheartj/ehz316
Martens P, Nuyens D, Rivero-Ayerza M, Van Herendael H, Vercammen J, Ceyssens W, Luwel E, Dupont M, Mullens W. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol 2019;108(10):1074-82. doi: 10.1007/s00392-019-01440-y
pubmed: 30788621
doi: 10.1007/s00392-019-01440-y
Zabel M, Willems R, Lubinski A, Bauer A, Brugada J, Conen D, Flevari P, Hasenfulb G, Svetlosak M, Huikuri HV, Malik M, Palovic N, Schmidt G, Sritharan R, Schologl S, Szavit-Nossan J, Traykov V, Tuinenburg AE, Willich SN, Harden M, Friede T, Hastrup J, Svendsen JH, Sticherling C, Merkely B; and the EU-CERTICD Study Investigators. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J 2020:41:3437-47. doi:10.1093/eurheartj/ehaa226
pubmed: 32372094
doi: 10.1093/eurheartj/ehaa226
Dagres N, Peek N, Leclercq C, Hindricks G. The PROFID project. Eur Heart J 2020;41(39):3781-82. doi: 10.1093/eurheartj/ehaa645
pubmed: 32949462
doi: 10.1093/eurheartj/ehaa645
Packer M. What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? Eur Heart J 2020;41:1757-63.
pubmed: 31390006
doi: 10.1093/eurheartj/ehz553
Goldenberg I, Huang DT, Nielsen JC. The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome. Eur Heart J 2020;41:2003-11.
doi: 10.1093/eurheartj/ehz788
Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012;367(24):2275-83. doi: 10.1056/NEJMoa1211107
pubmed: 23131066
doi: 10.1056/NEJMoa1211107
Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, Poole J, Boriani G, Costa R, Deharo JC, Epstein LM, Sa´ghy L, Snygg-Martin U, Starck C, Tascini C, Strathmore N. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;41:2012-32.
doi: 10.1093/eurheartj/ehaa010
Barra S, Boveda S, Providência R, Sadoul N, Duehmke R, Reitan C, Borgquist R, Narayanan K, Hidden-Lucet F, Klug D, Defaye P, Gras D, Anselme F, Leclercq C, Hermida JS, Deharo JC, Looi KL, Chow AW, Virdee M, Fynn S, Le Heuzey JY, Marijon E, Agarwal S; French-UK-Sweden CRT Network. Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate. J Am Coll Cardiol 2017;69(13):1669-78. doi: 10.1016/j.jacc.2017.01.042
pubmed: 28359511
doi: 10.1016/j.jacc.2017.01.042
Amara N, Boveda S, Defaye P, Klug D, Treguer F, Amet D, Perier MC, Gras D, Algalarrondo V, Bouzeman A, Piot O, Deharo JC, Fauchier L, Babuty D, Bordachar P, Sadoul N, Marijon E, Leclercq C; DAI-PP Investigators. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death. Europace 2018;20(1):65-72. doi: 10.1093/europace/euw379
pubmed: 28082419
doi: 10.1093/europace/euw379
Weeke P, Johansen JB, Jørgensen OD, Nielsen JC, Møller M, Videbaek R, Højgaard MV, Riahi S, Jacobsen PK. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register. Europace 2013;15(8):1150-7. doi: 10.1093/europace/eut017
pubmed: 23407630
doi: 10.1093/europace/eut017
Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32(3):695-703. doi: 10.1016/s0735-1097(98)00297-6
pubmed: 9741514
doi: 10.1016/s0735-1097(98)00297-6
Barra S, Narayanan K, Garcia R, Marijon E. Time to revisit implantable cardioverter-defibrillator implantation criteria in women. Eur Heart J 2020:ehaa970. doi: 10.1093/eurheartj/ehaa970
pubmed: 33367695
doi: 10.1093/eurheartj/ehaa970